Science News | COVID-19 Vaccine Activates Antibodies That Target Parts of the Virus: Study

Washington [US], July 5 (ANI): Considering the speculation about whether the SARS-CoV-2 vaccine can reawaken previous antibody responses and pave the way to a universal coronavirus vaccine, new research on a COVID-19 vaccine's antibody response suggests that the immune system's history with other coronaviruses, along with those behind the common cold, influences a patient's response, as per the study published in Cell Reports.

Led by scientists at the Translational Genomics Research Institute (TGen), part of City of Hope, and Northern Arizona University (NAU), a research team found that the vaccine generates antibodies that target regions of the SARS-CoV-2 spike protein that are unique to the new virus, while also targeting regions of the protein that are shared or conserved among many coronaviruses.

Also Read | IND vs ENG 5th Test: 8 Memorable Moments of Epic Series Finale at Edgebaston.

What's more, the antibody response to these different coronaviruses appears to follow different paths. Over the course of 140 days following vaccination, the response to common cold coronaviruses started early but diminished over time. The response to SARS-CoV-2 continued to get stronger and stronger over time.

"The findings could help fine-tune the design of future vaccines or new monoclonal antibody treatments, perhaps leading to a universal coronavirus vaccine," said John Altin, Ph.D., senior author and assistant professor in TGen's Pathogen Genomics and Integrated Cancer Genomics Divisions.

Also Read | Gay Couple Gets Married in Traditional Ceremony in Kolkata, Viral Wedding Wins Hearts on Internet.

"Even if the response to the conserved regions is just a small part of the vaccine's overall protection, it may be a response that could be leveraged in future vaccines against future variants of the COVID-19 virus," he added.

Altin and colleagues are now looking more closely at the antibodies that target the two conserved regions they identified in their study to determine whether these are broadly neutralizing antibodies that generate immunity extending to new variants of the virus.

Using a technology called PepSeq developed by Altin and co-author Jason Ladner, Ph.D., an assistant professor at NAU's Pathogen and Microbiome Institute, allowed the researchers to carefully map antibody responses and track them serially over 140 days in 21 people who received the Moderna SARS-CoV-2 vaccine. The technology matches individual peptides (the building blocks of proteins) with unique DNA tags. The tags allow scientists to pinpoint which peptides are being targeted by antibodies.

Before technologies like PepSeq, researchers had to measure the response of antibodies against one protein target at a time.

"PepSeq allows us to perform up to hundreds of thousands of measurements of antibodies against different parts of virus proteins all at the same time from the same sample," Ladner said.

PepSeq also helps scientists precisely map the antibody response to specific regions of a protein. This allowed Ladner, Altin and their colleagues to track the differences in antibody response between divergent and conserved regions of the SARS-CoV-2 Spike protein.

"Our theory is that there is actually memory from previous common cold coronavirus encounters, and when you get the vaccine for SARS-CoV-2, the vaccine reawakens some of those memories. Then you see this early response which is basically just a rapid memory response to what you've already seen," Altin said. "With time, the immune system can reshape those responses more in the direction of the pandemic virus."

Before COVID-19, Ladner and Altin were using PepSeq to get a closer look at the full range of viruses that infect humans. The powerful technology offers a way to "understand something about the viruses that a person has been exposed to in the past and the immune response to those infections," Ladner said.

For instance, Ladner and his colleagues are looking at whether some chronic diseases, such as Type 1 diabetes and celiac disease, might have some of their roots in different viral exposures. They also use the technology to look for different rates of infection between different populations, to see how this exposure history might be related to health disparities between those populations. (ANI)

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)